NCT01186861 / 2010-020916-12: Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy |
|
|
| Completed | 2 | 205 | Canada, US, Europe, RoW | OSI-906, erlotinib, OSI-774, Tarceva, placebo | Astellas Pharma Inc | Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | 07/13 | 03/15 | | |
NCT01533181: Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer |
|
|
| Completed | 2 | 44 | US, RoW | Laboratory Biomarker Analysis, Linsitinib, IGF-1R inhibitor OSI-906, OSI-906, OSI-906AA, Pharmacological Study, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral) | National Cancer Institute (NCI) | Recurrent Small Cell Lung Carcinoma | 11/14 | 11/14 | | |